重组人p53腺病毒注射液治疗晚期卵巢癌的疗效观察  

Clinical observation on recombinant adenoviral human p53 gene therapy for advanced ovarian cancer

作　　者：何婉[1] 许瑞莲[1] 朱莲玉[1] 刘积良 申维玺[1] 夏俊贤[1] 陈敬华[1] 朱美琴[1] 刘利平[3] 

机构地区：[1]深圳市人民医院肿瘤科,深圳518020 [2]深圳市流花医院肿瘤科,深圳518002 [3]深圳市人民医院肝胆外科,深圳518020

出　　处：《中国肿瘤临床与康复》2015年第7期782-785,共4页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨重组人p53腺病毒注射液治疗晚期卵巢癌的近期疗效。方法 2009年5月至2010年12月间收治的20例晚期卵巢癌患者给予重组人p53腺病毒注射液局部或全身治疗±化疗±热疗治疗,每2个月评价疗效。结果随访12个月,20例晚期卵巢癌中,完全缓解（CR）4例（20.0%）,部分缓解（PR）9例（45.0%）,稳定（SD）5例（25.0%）,进展（PD）2例（10.0%）。18例恶性胸、腹腔积液患者中,CR 5例（27.8%）,PR 7例（38.9%）,SD 6例（33.3%）。患者总体不良反应轻微,Ⅰ~Ⅱ度自限性发热12例。结论重组人p53腺病毒注射液联合化疗治疗晚期卵巢癌患者疗效好,不良反应可控。Objective To evaluate the short-term efficacy of recombinant human Ad-p53 agent （Gendicine？） in patients with advanced ovarian cancer. Methods Twenty patients with advanced ovarian cancer were recruited from Sheuzhen Liuhua Hospital during May 2009 and Octocber 2010. All patients were treated by Gendicine alone or combined with chemotherapy or hyperthermia. Response evaluation in- cluding change of tumor size and clinical benefit response were performed every 2 months. Results During 12-month follow-up, 4/20 （20. 0% ） patients reached complete response （CR）, 9/20 （45.0%） partial re- sponse （PR） , 5/20 （25.0%） stable disease （SD） and 2/20 （ 10. 0% ） progressive disease （PD）. A- mong 18 patients with malignant pleural or peritoneal effusion treated with Gendicine combined with chemo- therapy or hyperthermia, 5/18 （27. 8% ） achieved CR, 7/18 （38.9%） PR,6/18 （33.3%） SD. Conclu- sion Recombinant human Ad-p53 agent combined with chemotherapy is an effective and tolerant way to treat patients with advanced ovarian cancer.

关 键 词：重组人P53腺病毒注射液 晚期卵巢癌 恶性胸腹腔积液 

分 类 号：R737.31[医药卫生—肿瘤]